诺和诺德发布2025年财报：司美格鲁肽销售额2282.88亿丹麦克朗

Core Viewpoint - Novo Nordisk reported a strong financial performance for the year 2025, with significant sales growth driven by its semaglutide product line [1] Group 1: Financial Performance - Total sales for Novo Nordisk reached 309.1 billion Danish Krone, reflecting a 10% growth at constant exchange rates [1] - Sales from the entire semaglutide product line amounted to 228.288 billion Danish Krone [1] Group 2: Product Sales Breakdown - Sales of the diabetes version of semaglutide injection, Ozempic (known as 诺和泰 in China), reached 127.089 billion Danish Krone [1] - Sales of the weight loss version of semaglutide injection, Wegovy (known as 诺和盈 in China), totaled 79.106 billion Danish Krone [1] - Sales of the oral semaglutide tablet (known as 诺和忻 in China) were 22.093 billion Danish Krone [1] Group 3: Market Introduction - The Wegovy tablet, a once-daily oral semaglutide 25mg, was launched in the U.S. on January 5, with a total weekly prescription volume reaching approximately 50,000 [1]